Selection of a subpopulation with fewer DNA topoisomerase IIα gene copies in a doxorubicin-resistant cell line panel

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 502-507

  Withoff, S ^a   Keith, W N ^b   Knol, A J ^a   Coutts, J C ^b   Hoare, S F ^b   Mulder, N H ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

DNA topoisomerase II ; Doxorubicin; Fluorescence in situ hybridisation; GLC4; TopoII

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; MESSENGER RNA;

ARTICLE; CELL LINE; CELL SELECTION; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0029781038     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.393     Document Type: Article

References (39)

1. AUSTIN CA, SNG JH, PATEL S AND FISHER LM. (1993). Novel HeLa topoisomerase II is the IIβ isoform: complete coding sequence and homology with other type II topoisomerases. Biochim. Biophys. Acta., 1172, 283-291.
2. BECK WT, DANKS MK, WOLVERTON JS, KIM R AND CHEN M. (1993). Drug resistance associated with altered DNA topoisomerase II. Adv. Enzyme Regul., 33, 113-127.
3. BINASCHI M, GIACCONE G, GAZDAR AF, DE ISABELLA P, ASTALDI RICOTTI GCB, CAPRANICO G AND ZUNINO F. (1992). Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line. J. Natl Cancer Inst., 84, 1710 - 1716.
4. COUTTS J, PLUMB JA, BROWN R AND KEITH WN. (1993). Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br. J. Cancer, 68, 793-800.
5. D'ARPA P AND LIU LF. (1989). Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta, 989, 163-177.
6. DAVIES SM, ROBSON CN, DAVIES SL AND HICKSON ID. (1988). Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J. Biol. Chem., 263, 17724 - 17729.
7. DEFFIE AM, BATRA JK AND GOLDENBERG GJ. (1989). Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res., 49, 58-66.
8. DE JONG S, ZILJSTRA JG, DE VRIES EGE AND MULDER NH. (1990). Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res., 50, 304-309.
9. DE JONG S, ZIJLSTRA JG, MULDER NH AND DE VRIES EGE. (1991). Lack of cross-resistance to forstriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother. Pharmacol., 28, 461- 464.
10. DE JONG S, KOOISTRA AJ, DE VRIES EGE, MULDER NH AND ZILJSTRA JG. (1993). Topoisomerase II as a target of VM-26 and 4′-(9-acridinylamino)methane-sulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res., 53, 1064-1071.
11. DEXTER DL AND LEITH JT. (1986). Tumor heterogeneity and drug resistance. J. Clin. Oncol., 4, 244-257.
12. DRAKE FH, HOFMANN GA, BARTUS HF, MATTERN MR, CROOKE ST AND MIRABELLI CK. (1989). Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry, 28, 8154 - 8160.
13. EIJDEMS EWHM, DE HAAS M, COCO-MARTIN JM, OTTENHEIM CPE, ZAMAN GJR, DAUWERSE JG, BREUNING MH, TWENTYMAN PR, BORST P AND BAAS F. (1995). Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int. J. Cancer, 60, 676 - 684.
14. FRY AM, CHRESTA CM, DAVIES SM, WALKER MC, HARRIS AL, HARTLEY JA, MASTERS JR AND HICKSON ID. (1991). Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res., 51, 6592 - 6595.
15. HANN SR AND EISENMAN RN. (1984). Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Cell Biol., 4, 2486-2497.
16. HUSAIN I, MOHLER JL, SEIGLER HF AND BESTERMAN JM. (1994). Elevation of topoisomerase I mRNA, protein and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54, 539 - 546.
17. JENKINS JR, AYTON P, JONES T, DAVIES SL, SIMMONS DL, HARRIS AL, SHEER D AND HICKSON ID. (1992). Isolation of cDNA clones encoding the beta-isozyme of human DNA topoisomerase-II and localization of the gene to chromosome 3p24. Nucleic Acids Res., 20, 5587-5592.
18. KALLIONIEMI OP, KALLIONIEMI A, KURISU W, THOR A, CHEN LC, SMITH HS, WALDMAN FM, PINKEL D AND GRAY JW. (1992). ErbB2 amplification in breast cancer analysed by fluorescence in situ hybridization. Proc. Natl Acad. Sci. USA, 89, 5321-5325.
19. KEITH WN, DOUGLAS F, WISHART GC, MCCALLUM HM, GOERGE WD, KAYE SB AND BROWN R. (1993). Co-amplification of erbB2, Topoisomerase IIα and retinoic acid receptor α genes in breast cancer and allelic loss at Topoisomerase I on chromosome 20. Eur. J. Cancer, 29a 1469 - 1475.
20. KIMURA K, SAIJO M, UI M AND ENOMOTO T. (1994). Growth state-and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J. Biol. Chem., 269, 1173-1176.
21. LEHRACH H. (1990). In Genome Analysis. Vol 1: Genetic and physical mapping. Davies KE and Tilghman SM. (eds) pp. 39-81. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York.
22. LÖNN U, LÖNN S, NILSSON B AND STENKVIST B. (1994). Intratumoral heterogeneity for amplified genes in human breast carcinoma. Int. J. Cancer, 58, 40 - 45.
23. MEIJER C, MULDER NH, TIMMER-BOSSCHA H, ZIJLSTRA JG AND DE VRIES EGE. (1987). Role of free radicals in an adriamycin-resistant human small cell lung cancer cell line. Cancer Res., 47, 4613-4617.
24. MEIJER C, MULDER NH, TIMMER-BOSSCHA H, PETERS WHM AND DE VRIES EGE. (1991). Combined in vitro modulation of adriamycin resistance. Int. J. Cancer. 49, 582 - 586.
25. MÜLLER M, MEIJER C, ZAMAN GJR, BORST P, SCHEPER RJ, MULDER NH, DE VRIES EGE AND JANSEN PLM. (1994). Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl Acad. Sci. USA, 19, 13033-13037.
26. MURPHY DS, MCHARDY P, COUTTS J, MALLON EA, GEORGE WD, KAYE SB, BROWN R AND KEITH WN. (1995). Interphase cytogenetic analysis of erbB2 and TopoIIα co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int. J. Cancer, 64, 18 - 26.
27. NEDERLOF PM, VAN DER FLIER S, RAAP AK AND TANKE HJ. (1992). Quantification of inter and intra-nuclear variation of fluorescence in situ hybridization signals. Cytometry, 13, 831-838.
28. PEDERSEN-BJERGAARD J, JOHANSSON B AND PHILIP P. (1994). Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation. Cancer Genet. Cytogenet., 76, 50 - 55.
29. POMMIER Y, LETEURTRE F, FESEN MR, FUJIMORI A, BERTRAND R, SOLARY E, KOHLHAGEN G AND KOHN KW. (1994). Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12, 530 - 542.
30. RITKE MK AND YALOWICH JC. (1993). Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem. Pharmacol., 46, 2007 - 2020.
31. SAMBROOK J, FRITSCH EF AND MANIATIS T. (1989). Molecular Cloning, A Laboratory Manual. Second ed. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York.
32. TAN KB, MATTERN MR, ENG WK, MCCABE FL AND JOHNSON RK. (1989). Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl Cancer Inst., 81, 1732 - 1735.
33. TAN KB, DORMAN TE, FALLS KM, CHUNG TDY, MIRABELLI CK, CROOKE ST AND MAO J. (1992). Topoisomerase-IIα and topoisomerase-IIβ genes - characterization and mapping to human chromosome-17 and chromosome-3, respectively. Cancer Res., 52, 231 - 234.
34. TSUJI T, MIMURA Y, MAEDA K, IDA M, SASAKI K AND SHINOZAKI F. (1994). Numerical aberrations of chromosome 17 detected by FISH with DNA-specific probe in oral tumors. Anticancer Res., 14, 1689 - 1694.
35. 4 sublines with increasing adriamycin resistance. Int. J. Cancer, 61, 375 - 380.
36. WITHOFF S, SMIT EF, MEERSMA GJ, VAN DEN BERG A, TIMMER-BOSSCHA H, KOK K, POSTMUS PE, MULDER NH, DE VRIES EGE AND BUYS CHCM. (1994). Quantitation of DNA topoisomerase IIα messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. Lab. Invest., 71, 61 - 66.
37. WOESSNER RD, CHUNG TDY, HOFMANN GA, MATTERN MR, MIRABELLI CK, DRAKE FH AND JOHNSON RK. (1990). Differences between normal and ras-transformed NIH-3T3 cells in expression of 170 kD and 180 kD forms of topoisomerase II. Cancer Res., 50, 2901 - 2908.
38. ZIJLSTRA JG, DE VRIES EGE AND MULDER NH. (1987). Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res., 47, 1780-1784.
39. ZINI N, SANTI S, OGNIBENE A, BAVELLONI A, NERI LM, VALMORI A, MARIANI E, NEGRI C, ASTALDI-RICOTTI GC AND MARALDI NM. (1994). Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp. Cell Res., 210, 336-348.